Sun Wenjuan, Zhuang Zexiang, Yang Li, Zhou Jie, Zhang Linan, Yuan Junhua
Health Management Center, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
Gariatric Ward, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, China.
BMC Complement Med Ther. 2025 Apr 11;25(1):133. doi: 10.1186/s12906-025-04874-2.
This meta-analysis is aimed to verify the effectiveness and safety of Photobiomodulation (PBM) on body measurements, metabolic indicators, and inflammation indicators in obese patients across randomized controlled trials with various comparators.
From the inception of databases to January 5, 2025, we conducted a comprehensive literature search across PubMed, OVID, Cochrane, Embase, Web of Science, LILACS, Chinese Scientific Journals Database (VIP), Wanfang and China National Knowledge Infrastructure (CNKI). Two reviewers independently performed the search, extracted data, and assessed study quality based on predefined inclusion and exclusion criteria. Data analysis was carried out using Review Manager 5.4 software. The reporting and quality assessment of this review study was guided by the PRISMA and AMSTAR.
Eleven RCTs with a total of 569 patients were included in meta-analysis. The pooled data revealed that PBM demonstrated significantly improvements in body anthropometric measurements, such as waistline [MD = - 7.28, 95% CI (- 9.97 to - 5.67), p < 0.00001], weight [MD = - 3.54, 95% CI (- 5.97 to - 1.11), p < 0.00001], BMI [MD = - 1.18, 95% CI (- 1.93 to - 0.43), p = 0.002]. PBM also showed potential in the reduction of CRP [MD = - 0.99, 95% CI (- 1.17 to - 0.82), p < 0.00001], as well as in TC, and HOMA-IR, which is [MD = - 23.01, 95% CI (- 31.68 to - 14.35), p < 0.00001] and [MD = - 0.46, 95% CI (- 0.73 to - 0.20), p = 0.0007] respectively. No significant differences were found in reducing WHR [MD = - 0.05, 95% CI (- 0.1 to 0.00), p = 0.05], fat mass percentage [MD = - 0.28, 95% CI (- 1.25 to 0.69), p = 0.57] and insulin [MD = - 1.98, 95% CI (- 4.20 to 0.23), p = 0.08].
The results of our study suggest that PBM may offer potential benefits for treating obesity, showing some improvements in key indicators such as BMI, weight, waist circumference, CRP, TC, and HOMA-IR compared to exercise, dietary changes, and sham PBM. However, further theoretical exploration of PBM is needed, and multi-center, large-scale trials with longer follow-up durations and demographic range are necessary to confirm and validate the findings of our study. REGISTRATION NUMBER: CRD42024532988.
本荟萃分析旨在通过各项对照的随机对照试验,验证光生物调节疗法(PBM)对肥胖患者身体测量指标、代谢指标和炎症指标的有效性和安全性。
从数据库建立至2025年1月5日,我们对PubMed、OVID、Cochrane、Embase、Web of Science、LILACS、中国科学期刊数据库(维普)、万方和中国知网进行了全面的文献检索。两名评审员根据预先设定的纳入和排除标准独立进行检索、提取数据并评估研究质量。使用Review Manager 5.4软件进行数据分析。本综述研究的报告和质量评估以PRISMA和AMSTAR为指导。
11项随机对照试验共纳入569例患者进行荟萃分析。汇总数据显示,PBM在身体测量指标方面有显著改善,如腰围[MD = -7.28,95%CI(-9.97至-5.67),p < 0.00001]、体重[MD = -3.54,95%CI(-5.97至-1.11),p < 0.00001]、体重指数[MD = -1.18,95%CI(-1.93至-0.43),p = 0.002]。PBM在降低C反应蛋白[MD = -0.99,95%CI(-1.17至-0.82),p < 0.00001]以及总胆固醇和胰岛素抵抗指数方面也显示出潜力,分别为[MD = -23.01,95%CI(-31.68至-14.35),p < 0.00001]和[MD = -0.46,95%CI(-0.73至-0.20),p = 0.0007]。在降低腰臀比[MD = -0.05,95%CI(-0.1至0.00),p = 0.05]、脂肪量百分比[MD = -0.28,95%CI(-1.25至0.69),p = 0.57]和胰岛素[MD = -1.98,95%CI(-4.20至0.23),p = 0.08]方面未发现显著差异。
我们的研究结果表明,与运动、饮食改变和假PBM相比,PBM在治疗肥胖方面可能具有潜在益处,在体重指数、体重、腰围、C反应蛋白、总胆固醇和胰岛素抵抗指数等关键指标上有一定改善。然而,需要对PBM进行进一步的理论探索,有必要开展多中心、大规模且随访时间更长、涵盖更广泛人群的试验来证实和验证本研究结果。注册号:CRD42024532988。